查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606697

糖尿病黄斑部水肿治疗市场：依治疗方法、最终用户分类 - 全球预测 2025-2030

Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年糖尿病黄斑部水肿治疗市值为29.7亿美元，预计2024年将达31.2亿美元，复合年增长率为5.11%，预计到2030年将达到42.2亿美元。

糖尿病黄斑部水肿（DME）治疗市场包括开发和部署旨在控制黄斑肿胀的治疗解决方案，黄斑部肿胀是糖尿病患者视力障碍的主要原因。全球糖尿病盛行率的上升凸显了对有效 DME 治疗的需求，这增加了相关眼部併发症的发生率。这些治疗对于保护视力、改善生活品质和减轻与糖尿病相关的医疗负担至关重要。应用范围包括抗 VEGF 注射、皮质类固醇和雷射治疗等药物干预，主要由专业眼科中心和医院的医疗保健专业人员使用。该领域的主要成长动力包括对糖尿病视网膜病变认识的提高、治疗方案的进步以及使治疗更实惠和容易获得的支持性医疗政策。此外，世界人口老化，更容易患糖尿病，正在推动需求。

主要市场统计
基准年[2023] 29.7亿美元
预测年份 [2024] 31.2亿美元
预测年份 [2030] 42.2亿美元
复合年增长率（%） 5.11%

最近在以患者为中心的治疗方法（例如持续给药系统和生技药品）中出现了机会，并且与正在进行的精准医学研究一致。为了利用这些优势，公司应该投资研发和伙伴关係关係，并专注于药物配方和综合治疗方法的创新。然而，这个市场面临一些挑战，例如先进治疗的高成本、报销问题以及治疗的潜在副作用，这可能会限制治疗的采用。监管障碍也减缓了新治疗方法推向市场的速度。未来的创新应着重于非侵入性治疗方法和综合护理方法，也可能结合数位健康技术来加强病患监测和结果。从竞争格局来看，市场较为分散，主要企业不断寻求透过技术进步和策略联盟来实现差异化。总体而言，DME治疗市场的成长取决于技术创新和可近性之间的平衡，拥抱技术进步和解决患者负担对于永续业务成长仍然至关重要。

市场动态：快速发展的糖尿病黄斑部水肿治疗市场的关键市场洞察

供需的动态交互作用正在改变糖尿病黄斑部水肿治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 由于老年人口增加导致全球糖尿病盛行率上升
    • 提高对糖尿病视网膜病变和糖尿病黄斑部水肿的认识
    • 政府主导的提高对糖尿病视网膜病变认识的倡议
  • 市场限制因素
    • DME处理成本高
  • 市场机会
    • 更多引入新的和先进的治疗方案
    • 改善 DME 治疗的报销政策和医疗保健覆盖范围
  • 市场挑战
    • DME 治疗临床试验设计的挑战

波特五力：驾驭糖尿病黄斑部水肿治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解糖尿病黄斑部水肿治疗市场的外部影响

外部宏观环境因素在塑造糖尿病黄斑部水肿治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解糖尿病黄斑部水肿治疗市场的竞争格局

对糖尿病黄斑部水肿治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵糖尿病黄斑部水肿治疗市场供应商的绩效评估

FPNV定位矩阵是评估糖尿病黄斑部水肿治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了糖尿病黄斑部水肿治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对糖尿病黄斑部水肿治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化的加剧，全球糖尿病盛行率正在上升
      • 提高对糖尿病视网膜病变和糖尿病黄斑部水肿的认识
      • 政府主导的提高人们对糖尿病视网膜病变认识的倡议
    • 抑制因素
      • DME处理成本高
    • 机会
      • 增加新的先进治疗方法的引入
      • 完善 DME 治疗的报销政策和医疗保险
    • 任务
      • DME 治疗临床试验设计的挑战
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章糖尿病黄斑部水肿治疗市场（依治疗）

  • 皮质类固醇注射
  • 药物
  • 雷射治疗
  • 药物治疗

第七章糖尿病黄斑部水肿治疗市场：依最终使用者分类

  • 医院
  • 眼科诊所

第八章北美和南美糖尿病性黄斑部水肿治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区糖尿病性黄斑部水肿治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的糖尿病黄斑部水肿治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Adverum Biotechnologies
  • Aerpio Pharmaceuticals
  • Alcon Vision LLC
  • Alimera Sciences, Inc.
  • Arctic Vision
  • Bausch & Lomb Incorporated
  • Chugai Pharmaceutical Co., Ltd.
  • EyePoint Pharmaceuticals Inc. .
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Graybug Vision, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Kodiak Sciences Inc
  • Kubota Pharmaceutical Holdings Co. Ltd.
  • Novartis AG
  • Ocugen Inc.
  • Oculis Holding AG
  • Ocuphire Pharma, Inc.
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd.
  • YD Life Science
Product Code: MRR-2A0283E25681

The Diabetic Macular Edema Treatment Market was valued at USD 2.97 billion in 2023, expected to reach USD 3.12 billion in 2024, and is projected to grow at a CAGR of 5.11%, to USD 4.22 billion by 2030.

Diabetic Macular Edema (DME) treatment market encompasses the development and deployment of therapeutic solutions aimed at managing swelling in the macula, a primary cause of vision impairment among diabetic patients. The necessity for effective DME treatments is underscored by the rising global prevalence of diabetes, which increases the incidence of associated ocular complications. These treatments are crucial for preserving vision, improving life quality, and reducing healthcare burdens related to diabetes. The application scope includes pharmacological interventions like anti-VEGF injections, corticosteroids, and laser therapy, predominantly used by healthcare providers in specialized ophthalmic centers and hospitals. Key growth drivers in this domain include increased awareness about diabetic retinopathy, advancements in therapeutic options, and supportive health policies facilitating treatment affordability and access. Additionally, the aging global population prone to diabetes catalyzes demand.

KEY MARKET STATISTICS
Base Year [2023] USD 2.97 billion
Estimated Year [2024] USD 3.12 billion
Forecast Year [2030] USD 4.22 billion
CAGR (%) 5.11%

Recent opportunities are emerging in patient-centric modalities such as sustained drug delivery systems and biologics, aligning with ongoing research in precision medicine. To leverage these, companies should invest in R&D and partnerships focusing on innovation in drug formulations and comprehensive treatment regimens. However, the market faces challenges like high costs of advanced therapies, reimbursement issues, and potential side effects of treatments that may restrain uptake. Regulatory hurdles can also slow the introduction of novel therapies into the market. Future innovation should focus on non-invasive treatment methods and integrated care approaches, potentially incorporating digital health technologies to enhance patient monitoring and outcomes. Insight into the competitive landscape reveals a fragmented market, with key players constantly striving for differentiation through technology advancement and strategic collaborations. Overall, the growth of the DME treatment market hinges on balancing innovation with accessibility, where embracing technological advancement and addressing patient affordability remain paramount for sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Macular Edema Treatment Market

The Diabetic Macular Edema Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising global prevalence of diabetes with increasing geriatric population
    • Increasing awareness of diabetic retinopathy and diabetic macular edema
    • Government-led initiatives to raise awareness about diabetic retinopathy
  • Market Restraints
    • High treatment costs of DME treatments
  • Market Opportunities
    • Increasing introduction of new and advanced treatment options
    • Improved reimbursement policies and healthcare coverage for DME treatments
  • Market Challenges
    • Clinical trial design challenges for DME treatments

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Macular Edema Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Macular Edema Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Macular Edema Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Macular Edema Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Macular Edema Treatment Market

A detailed market share analysis in the Diabetic Macular Edema Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Macular Edema Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Macular Edema Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Macular Edema Treatment Market

A strategic analysis of the Diabetic Macular Edema Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Macular Edema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Aerpio Pharmaceuticals, Alcon Vision LLC, Alimera Sciences, Inc., Arctic Vision, Bausch & Lomb Incorporated, Chugai Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals Inc. ., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Graybug Vision, Inc., KalVista Pharmaceuticals, Inc., Kodiak Sciences Inc, Kubota Pharmaceutical Holdings Co. Ltd., Novartis AG, Ocugen Inc., Oculis Holding AG, Ocuphire Pharma, Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd., and YD Life Science.

Market Segmentation & Coverage

This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Corticosteroid Injections, Drugs, Laser Treatment, and Pharmacological Treatment.
  • Based on End-User, market is studied across Hospitals and Ophthalmology Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
      • 5.1.1.2. Increasing awareness of diabetic retinopathy and diabetic macular edema
      • 5.1.1.3. Government-led initiatives to raise awareness about diabetic retinopathy
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs of DME treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing introduction of new and advanced treatment options
      • 5.1.3.2. Improved reimbursement policies and healthcare coverage for DME treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical trial design challenges for DME treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Macular Edema Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroid Injections
  • 6.3. Drugs
  • 6.4. Laser Treatment
  • 6.5. Pharmacological Treatment

7. Diabetic Macular Edema Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ophthalmology Clinics

8. Americas Diabetic Macular Edema Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Macular Edema Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Macular Edema Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adverum Biotechnologies
  • 3. Aerpio Pharmaceuticals
  • 4. Alcon Vision LLC
  • 5. Alimera Sciences, Inc.
  • 6. Arctic Vision
  • 7. Bausch & Lomb Incorporated
  • 8. Chugai Pharmaceutical Co., Ltd.
  • 9. EyePoint Pharmaceuticals Inc. .
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Graybug Vision, Inc.
  • 14. KalVista Pharmaceuticals, Inc.
  • 15. Kodiak Sciences Inc
  • 16. Kubota Pharmaceutical Holdings Co. Ltd.
  • 17. Novartis AG
  • 18. Ocugen Inc.
  • 19. Oculis Holding AG
  • 20. Ocuphire Pharma, Inc.
  • 21. Oxurion NV
  • 22. Pfizer Inc.
  • 23. Regeneron Pharmaceuticals Inc
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. YD Life Science

LIST OF FIGURES

  • FIGURE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC MACULAR EDEMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023